OPEN SESSION
Venue: Hilton Montreal Bonaventure, Montreal
Room: Outremont
Date: Sunday, April 30th, 2006
Time: 8:30 am – 2:45 pm
Chair: Dr. Malcolm Moore

8:30 am  WELCOME AND INTRODUCTION  Dr. M. Moore

8:35 am  CLOSED TRIALS

**CO.19**: A Phase III Randomized Double-Blind Placebo-Controlled Trial of FOLFOX with or without PTK 787 after Curative Resection for Patients with Stage III Colon Cancer  Dr. M. Moore

**PA.4**: A Phase III, Multi-centre, Double-Blind, Placebo-Controlled Study of AMG 706 plus Gemcitabine and Erlotinib in Patients with Unresectable Locally Advanced or Metastatic Pancreatic Cancer  Dr. M. Moore

**CO.16 (MRC CR07)**: Pathology-guided Treatment in Rectal Cancer - A randomised trial comparing pre-operative radiotherapy and selective post-operative chemoradiotherapy in rectal cancer  Dr. J. Couture

**CO.17**: A Phase III Randomized Study of Cetuximab (Erbitux\textsuperscript{TM}, C225) and Best Supportive Care versus Best Supportive Care in Patients with Pretreated Metastatic Epidermal Growth Factor Receptor (EGFR)-Positive Colorectal Carcinoma  Dr. D. Jonker

**PAC.1 (SWOG-S0205)**: A Randomized Placebo Controlled Study of Cetuximab plus Gemcitabine in Patients with Locally Advanced, Unresectable or Metastatic Pancreatic Cancer  Dr. Ralph Wong

**PAC.2 (ECOG-E4201)**: A Randomized Phase III Study of Gemcitabine in Combination with Radiation Therapy versus Gemcitabine Alone in Patients with Localized, Unresectable Pancreatic Cancer  Dr. J. Biagi

9:00 am  ACTIVE TRIALS

**ES.2 (TROG 03.01)**: A Randomised Phase III Study in Advanced Oesophageal Cancer to Compare Quality of Life and palliation of Dysphagia in Patients Treated with Radiotherapy versus Chemo-Radiotherapy  Dr. Rebecca Wong

**PA.2 (ESPAC-3)**: Adjuvant Chemotherapies in Resectable Pancreatic Cancer  Dr. M. Moore
9:15 am **ENDORSED CTSU TRIALS**

**GAC.1** (CALGB-80101): A Phase III Trial of Adjuvant Chemoradiation After Resection of Gastric Or Gastroesophageal Adenocarcinoma

Dr. G. Bjarnason

**CRC.2** (NCCTG N0147): A Randomized Phase III Trial of Irinotecan (CPT-11) and/or Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) with or without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer

Dr. S. Gill

**CRC.3** (ECOG E5202): A Randomized Phase III Study Comparing 5-FU Leucovorin and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers.

Dr. C. Butts

**CRC.4** (ECOG E5204): Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Pre-operative Chemoradiation.

Dr. J. Couture

9:45 am **UPDATE - ENDORSING AND PARTICIPATING IN CTSU TRIALS**

Dr. C. O’Callaghan

9:55 am **TRIALS IN DEVELOPMENT**

**CO.18**: A Phase II Study of AZD2171 and Capecitabine versus Capecitabine Alone as 1st Line Therapy in Patients with Metastatic Colorectal Cancer

Dr. C. Cripps

**BI.1**: A Phase III Study of Gemcitabine Plus Capecitabine (GEMCAP) versus Gemcitabine Alone in Advanced Biliary Cancer

Dr. J. Knox

**CO.20**: A Phase III Randomized Study of BMS582664 and Cetuximab (ErbituxTM) versus Cetuximab in Patients with Pretreated Metastatic Colorectal Carcinoma

Dr. L. Siu

10:30 am **REFRESHMENT BREAK**

11:00 am **DISCUSSION – CETUXIMAB IN CANADA**

Dr. M. Moore

11:15 am **DISEASE ORIENTED WORKING GROUP REPORTS / NEW TRIALS**

**IND**

Dr. Ralph Wong

Colon DOG

Dr. D. Jonker

12:00 pm **LUNCH**

1:00 pm **DISEASE ORIENTED GROUP REPORTS / NEW TRIALS (CONTINUED)**

Rectal DOG

Dr. J. Couture

Esophageal DOG

Dr. Rebecca Wong
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:15 pm</td>
<td>GI INTERGROUP UPDATE</td>
<td>Dr. M. Moore</td>
</tr>
<tr>
<td>2:30 pm</td>
<td>CLOSING REMARKS &amp; ADJOURNMENT</td>
<td>Dr. M. Moore</td>
</tr>
<tr>
<td>2:45 pm</td>
<td>CLOSED SESSION: GI EXECUTIVE MEETING</td>
<td>Dr. M. Moore</td>
</tr>
</tbody>
</table>